All In Biotech

Drug Trial Radar · NCT03646357

BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function

BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function (BETAMI)

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,895 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,895

Actual

Start

Oct 1, 2018

Primary completion

Apr 4, 2025

Study completion Dec 10, 2035

Sponsor

Lead sponsor
Oslo University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Vestre Viken Hospital Trust; The Hospital of Vestfold; University of Oslo; Helse Stavanger HF; Haukeland University Hospital; St. Olavs Hospital; University Hospital of North Norway; Sorlandet Hospital HF; Norwegian University of Science and Technology; Sykehuset Innlandet HF; Nordlandssykehuset HF; Lovisenberg Diakonale Hospital; Diakonhjemmet Hospital; Ostfold Hospital Trust
First posted
Aug 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to investigate whether oral betablocker (BB) therapy is superior to no such treatment following an acute myocardial infarction (AMI).

Conditions

  • Acute Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • ST Elevation Myocardial Infarction

Interventions

  • Non-betablockerOther

    No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.

  • BetablockerDrug

    A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be: * Metoprolol succinate up to a total dose of 200mg daily * Bisoprolol up to a total dose of 10mg daily * Carvedilol up to a total dose of 50mg daily The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite of death of any cause, recurrent myocardial infarction, incident heart failure, coronary revascularization, ischemic stroke, malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac originTime frame: 6 months (minimum) to 6 years (maximum)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Sørlandet Sykehus

    Arendal, Norway

  • Haukeland Universitetssykehus

    Bergen, Norway

  • Nordlandssykehuset HF Bodø

    Bodø, Norway

  • Drammen Hospital

    Drammen, Norway

  • Sykehuset Østfold Kalnes

    Fredrikstad, Norway

  • Sykehuset Innlandet HF, Gjøvik Sykehus

    Gjøvik, Norway

  • Sykehuset Innlandet Hamar

    Hamar, Norway

  • Vestre Viken HF, Ringerike Sykehus

    Hønefoss, Norway

  • Sykehuset Innlandet Lillehammer

    Lillehammer, Norway

  • AHUS

    Lørenskog, Norway

  • LHL Gardermoen

    Lørenskog, Norway

  • Diakonhjemmet Sykehus

    Oslo, Norway

  • Lovisenberg Diakonale Sykehus

    Oslo, Norway

  • Oslo University Hospital Rikshospitalet, Dept.of Cardiology

    Oslo, Norway

  • Oslo University Hospital Ullevaal, Dept. of Cardiology

    Oslo, Norway

  • Vestre Viken HF, Bærum Sykehus

    Sandvika, Norway

  • Stavanger Universitetssjukehus

    Stavanger, Norway

  • Vestfold hospital

    Tønsberg, Norway

  • Universitetssykehuset Nord-Norge, UNN

    Tromsø, Norway

  • St. Olavs University Hospital

    Trondheim, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.